Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299924 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL8199316 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL22003 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL7052601 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL5033222 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL2373879 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL734764 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL3999265 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL576335 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL8010246 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874727-A | Barium complex and preparation method and application thereof | 中国科学院赣江创新研究院 | 2025-04-25 | — | — | CN | claimed |
| CN-118995178-A | Functional surfactant for oil and gas field and preparation method thereof | 陕西邦希化工有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240139353-A1 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. (CA) | 2024-05-02 | — | — | US | claimed |
| CN-117181019-A | Nitrogen-containing hybrid macrocyclic cycloparaffin polyamide composite membrane, and preparation method and application thereof | 天津大学 | 2023-12-08 | — | — | CN | claimed |
| CN-116471853-A | Perovskite solar cell modified by nitrogenous cyclic molecules | 西北工业大学 | 2023-07-21 | — | — | CN | claimed |
| CN-114699930-B | Polyazacyclic amide membrane for dye wastewater treatment and preparation method thereof | 郑州大学 | 2023-04-14 | — | — | CN | claimed |
| WO-2023050008-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-04-06 | — | — | WO | claimed |
| WO-2023049985-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-04-06 | — | — | WO | claimed |
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2023-02-16 | — | — | US | claimed |
| CN-115364684-B | High-flux positively-charged nanofiltration membrane and preparation method thereof | 天津大学 | 2023-01-03 | — | — | CN | claimed |
| US-20040137638-A1 | Superoxide dismutase mimetic metal complexes in which the metal can coordinate axial ligands; mobile phase comprising an excess of a salt of a coordinating anion in a solvent system | GALERA THERAPEUTICS, LLC | 2004-07-15 | — | — | US | claimed |
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | CENTRE NATIONAL DE LA RECHERCHE-SCIENTIFIQUE (FR) | 2004-06-24 | — | — | US | claimed |
| EP-1405066-A1 | CHROMATOGRAPHY OF METAL COMPLEXES | Metaphore Pharmaceuticals Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1347964-A2 | TETRAETHER LIPID DERIVATIVES AND LIPOSOMES CONTAINING TETRAETHER LIPID DERIVATIVES AND LIPID AGGLOMERATES AND THE USE THEREOF | Bernina Biosystems GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| WO-2002071054-A1 | CHROMATOGRAPHY OF METAL COMPLEXES | METAPHORE PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | claimed |
| WO-2002053554-A2 | TETRAETHER LIPID DERIVATIVES AND LIPOSOMES CONTAINING TETRAETHER LIPID DERIVATIVES AND LIPID AGGLOMERATES AND THE USE THEREOF | BERNINA BIOSYSTEMS GMBH (DE) | 2002-07-11 | — | — | WO | claimed |
| US-6193950-B1 | FOR DIAGNOSIS AND THERAPY | SCHERING AG (DE) | 2001-02-27 | — | — | US | claimed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | claimed |
| WO-1990007261-A2 | PROCESS FOR PREPARING MONO-N-ALKYLATED POLYAZAMACROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | claimed |
| US-4001212-A | EXTRACT METAL IONS FROM SOLUTION AND COMPLEX | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | SCO2, IPO9, IPO4 | HIF1A 3377/4885MAPT 4676/4885PDE4A 4882/4885 |
| US-20240139353-A1 | METHODS OF TREATING CANCER | FGFR3, FGFR2, FGFR1 | HIF1A 469/4885MAPT 2485/4885PDE4A 4810/4885 |
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | IGF1R, IGFBP1, IGFBP2 | HIF1A 398/4885MAPT 3641/4885PDE4A 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.